## Clinical Case Analysis: Yolk Sac Tumor of the Ovary ### Clinical Presentation **Key Point:** The combination of: - Young female (adolescent) - Markedly elevated AFP (1200 ng/mL) with normal hCG - Mixed solid-cystic ovarian mass ...is pathognomonic for **yolk sac tumor (endodermal sinus tumor)**, the most common malignant ovarian GCT in children and adolescents. ### Correct Statements (Options 0, 1, 2) **Option 0: Epidemiology and Classification** - Yolk sac tumor is the most common malignant ovarian GCT in pediatric/adolescent populations - Accounts for ~40% of malignant GCTs in this age group - Highly aggressive but chemosensitive **Option 1: Pathognomonic Histology** - Schiller-Duval bodies are the hallmark of yolk sac tumor - Structure: papillary projections with central blood vessel, surrounded by cuboidal endodermal cells - This is a high-yield histologic finding for NEET PG **Option 2: Treatment and Chemosensitivity** - Surgical resection (unilateral salpingo-oophorectomy in young women to preserve fertility) followed by chemotherapy - BEP regimen (Bleomycin, Etoposide, Cisplatin) is standard - Yolk sac tumor is highly chemosensitive; response rates exceed 90% with modern regimens - Excellent prognosis with multimodal therapy ### Incorrect Statement (Option 3: Prognosis) **High-Yield:** The prognosis of yolk sac tumor has **dramatically improved** with modern chemotherapy. The statement claiming "<20% 5-year survival" reflects outdated pre-chemotherapy data. **Current Prognosis:** - With BEP chemotherapy, 5-year survival rates are **>90%** for early-stage disease - Even advanced-stage disease achieves 70–80% survival with multimodal therapy - The tumor is one of the most chemosensitive malignancies - Long-term follow-up uses **AFP** (not hCG, which is produced by choriocarcinoma/dysgerminoma) - LDH may be elevated but is not tumor-specific **Clinical Pearl:** Yolk sac tumor is a paradigm of a chemosensitive malignancy where prognosis has been transformed by platinum-based therapy. Outdated survival figures (pre-1980s) should not be cited in modern practice. ### Comparison: Prognostic Markers in Ovarian GCTs | Tumor Type | Marker | Prognosis with Modern Therapy | |---|---|---| | Dysgerminoma | LDH, mild hCG | >95% 5-year survival | | Yolk Sac Tumor | AFP | >90% 5-year survival (early-stage) | | Immature Teratoma | AFP (variable) | 70–90% (depends on grade) | | Choriocarcinoma | hCG | 70–80% (highly chemosensitive) | **Mnemonic:** **YEAST** = Yolk sac tumor, **Excellent** prognosis, **AFP** elevated, **Schiller-Duval** bodies, **Therapy**-responsive (BEP chemotherapy).
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.